Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
Clinical Pharmacology & Therapeutics · 2026-04 · 119 (4) · 997-1004
DOI: 10.1002/cpt.70182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.12.2025. Verfasst von Ruben Malmberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Nivolumab, Melanoma, Immune Checkpoint Inhibitors, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited. This study compares grade ≥3 immune‐related adverse events between standard and extended interval dosing of nivolumab in patients with melanoma and explores associated risk factors. This retrospective cohort study included patients with melanoma treated with nivolumab monotherapy from April 2016–September 2021 in the MULTOMAB study. Data on baseline characteristics and immune‐related adverse events were collected from patients’ electronic medical records with a maximum follow‐up of 6 months. A total of 236 patients (125 metastatic and 111 adjuvant) were included, with 146 in the standard cohort and 90 in the extended interval cohort. Grade ≥3 immune‐related adverse events occurred in 20 patients: 13 (8.9%) patients in the standard cohort and 7 (7.8%) in the extended interval cohort. No significant differences in grade ≥3 immune‐related adverse events were observed between the two cohorts ( P = 0.763). This study suggests that the risk of severe immune‐related adverse events is comparable between both interval dosing regimens of nivolumab in patients with melanoma. Therefore, the extended interval dosing of nivolumab appears to be safe for application in standard care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands.
- Department of Medical Oncology, Erasmus University Medical Centre, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
ORCID-Profile: Ruben Malmberg, Maaike M Hofman, Stefani Oosterveld, Esther Oomen-de Hoop, Astrid A M van der Veldt, Arjen Joosse, Roelof W F van Leeuwen, Ron H J Mathijssen
Zitieren
APA
Malmberg, R., Hofman, M. M., Ashad, F., Daloul, A., Oosterveld, S., Basak, E. A., Oomen-de Hoop, E., van der Veldt, A. A. M., Joosse, A., van Leeuwen, R. W. F., & Mathijssen, R. H. J. (2026). Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma. Clinical Pharmacology & Therapeutics, 119(4), 997-1004. https://doi.org/10.1002/cpt.70182
Vancouver
Malmberg R, Hofman MM, Ashad F, Daloul A, Oosterveld S, Basak EA, et al. Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma. Clinical Pharmacology & Therapeutics. 2026;119(4):997-1004. doi:10.1002/cpt.70182
BibTeX
@article{Malmberg2026,
author = {Malmberg, Ruben and Hofman, Maaike M and Ashad, Fatima and Daloul, Alaa and Oosterveld, Stefani and Basak, Edwin A and Oomen-de Hoop, Esther and van der Veldt, Astrid A M and Joosse, Arjen and van Leeuwen, Roelof W F and Mathijssen, Ron H J},
title = {Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {4},
pages = {997--1004},
doi = {10.1002/cpt.70182}
}
EUVIMED